News
-
NewsLonza expands manufacturing capacity for HPAPI and ADC payload-linkers
Investment at Lonza’s facility in Visp, Switzerland designed to meet increasing demand in the ADC market.
-
NewsSimplified C-glycosides synthesis could transform diabetes drug manufacturing
The two-step synthesis process offers a streamlined approach that removes longstanding barriers to scalable C-glycoside manufacture for SGLT2 inhibitors.
-
NewsPredictive stability modelling promising tool for optimising moisture-sensitive formulations
Research provides a data-driven foundation for excipient selection in drug formulation development, particularly solid dosage forms.
-
NewsGenentech’s Xofluza approved as first single-dose generic for influenza in US
FDA’s approval of generic baloxavir marboxil tablets for influenza broads access to a novel-mechanism antiviral for individuals aged five years and over.
-
NewsNovartis and Antares target undruggable oncology in $1.8bn deal
Agreement underlines growing investment in next-generation discovery platforms as pharma companies seek differentiated mechanisms of action in an increasingly competitive oncology landscape.
-
NewsEDQM removes rabbit pyrogen test references in revised OCABR guidelines
Guideline revisions support the EU’s ongoing transition away from using animals for in vivo testing of parenteral medicines.
-
NewsCARsgen wins first global approval of CAR T therapy for solid tumours
Approval of the autologous cell therapy satri-cel in China fills the gap in later-line treatment for advanced gastric cancer.
-
NewsPaulo Fontoura to lead research and development at Sanofi
Taking over from Dr Houman Ashrafian, the 25-year industry veteran will help to advance the firm’s innovation strategy.
-
NewsBiogen acquires immunology start-up RayThera for $1bn
Anti-inflammatory assets in the deal allow Biogen to expand immunology pipeline into new disease areas.
-
NewsFAP-targeted radiopharmaceuticals potential as next-gen treatment for multiple cancers
Innovative radiopharmaceuticals demonstrated “highly promising” survival benefit in study of participants with end-stage solid tumours.
-
NewsSandoz prepares for biosimilar ‘golden decade’ with new development centre in Slovenia
Opening of the new site represents the largest biosimilar development hub and supports Sandoz in building its in-house capabilities.
-
NewsRecipharm makes major investment to expand US sterile manufacturing footprint
Decision strengthens the CMDO’s fill-finish operations and increases capacity for biologics and advanced therapies.
-
NewsMHRA green lights lower dose EURneffy nasal spray for children
Needle-free allergy adrenaline treatment expands options beyond injection for younger UK patients for first time.
-
NewsPetri dish study could enhance accuracy of microbiological testing
Findings may help mitigate moisture-related issues when using Reasoner’s agar (R2A) during microbial water quality testing.
-
NewsMHRA targets medicine safety with new AI sandbox
Agency’s new AI initiative will provide an evidence-based programme to encourage pharmaceutical companies to invest in innovation in the UK.
-
NewsGSK advances oncology efforts with $10.6bn Nuvalent acquisition
Multi-product oncology deal accelerates GSK’s entry into lung cancer.
-
NewsGilead-MSD once-weekly oral HIV regimen meets Phase III endpoints
Combining islatravir/lenacapavir could provide alternative to daily antiretroviral therapy for virologically suppressed patients with HIV.
-
NewsRoche and Nurix to advance potential best-in-class BTK degrader bexobrutideg
Collaboration agreement expands Roche’s oncology pipeline and offers therapeutic potential across immunology and neurology.
-
NewsAmgen’s Imdylltra approved in Europe for aggressive solid tumour
Milestone authorisation represents the first T-cell engagement therapy for small cell lung cancer.
-
NewsCorrectSequence’s base-editing therapy shows preliminary success in sickle cell disease
Achievement of study’s primary efficacy endpoint positions therapy as potentially safer and more effective approach to CRISPR-based gene-editing therapies.